Log in

Relevant bibliographies by topics / Leishmaniose – Vaccination / Journal articles

To see the other types of publications on this topic, follow the link: Leishmaniose – Vaccination.

Journal articles on the topic 'Leishmaniose – Vaccination'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 journal articles for your research on the topic 'Leishmaniose – Vaccination.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

HUGNET, Christophe, Jean-Loup LEMESRE, Gérard PAPIEROK, and Gilles BOURDOISEAU. "Résultats de la vaccination contre la leishmaniose canine (Leishmania infantum) en zone d'enzootie." Bulletin de l'Académie vétérinaire de France, no. 1 (2006): 127. http://dx.doi.org/10.4267/2042/47822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Minodier, P., F. Faraut-Gambarelli, C. Nicaise, C. Gire, J. M. Garnier, and H. Dumon. "La vaccination contre les leishmanioses." Médecine et Maladies Infectieuses 30, no. 3 (2000): 141–45. http://dx.doi.org/10.1016/s0399-077x(00)88803-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

de Cosmo, A., D. Mazzoni, A. Canati, GE Magi, and D. Beghelli. "Cutaneous leishmaniosis in a dog vaccinated with LiESP/QA-21: effective or defective vaccine-related immune surveillance? A case report." Veterinární Medicína 62, No. 1 (2017): 48–51. http://dx.doi.org/10.17221/48/2016-vetmed.

Full text

Abstract:

Leishmania, an intracellular protozoan parasite, is endemic, widespread and represents a public health problem in most countries of the Mediterranean basin as it is implicated in a wide spectrum of diseases both in humans and animals. Vaccination of canines remains the best control strategy to counteract the progression of active infection for canine disease in areas of the world where transmission to humans is primarily zoonotic. This case report describes the history of a four-year-old dog vaccinated against canine leishmaniosis that was presented to a private clinic for the onset of a nodul

APA, Harvard, Vancouver, ISO, and other styles

4

Martínez-Rodrigo, Abel, Alicia Mas, Daniel Álvarez-Campos, José A. Orden, Gustavo Domínguez-Bernal, and Javier Carrión. "Epitope Selection for Fighting Visceral Leishmaniosis: Not All Peptides Function the Same Way." Vaccines 8, no. 3 (2020): 352. http://dx.doi.org/10.3390/vaccines8030352.

Full text

Abstract:

Visceral leishmaniosis (VL) caused by Leishmania infantum is a disease with an increasing prevalence worldwide. Treatments are expensive, toxic, and ineffective. Therefore, vaccination seems to be a promising approach to control VL. Peptide-based vaccination is a useful method due to its stability, absence of local side effects, and ease of scaling up. In this context, bioinformatics seems to facilitate the use of peptides, as this analysis can predict high binding affinity epitopes to MHC class I and II molecules of different species. We have recently reported the use of HisAK70 DNA immunizat

APA, Harvard, Vancouver, ISO, and other styles

5

Olobo, J. O., C. O. Anjili, M. M. Gicheru, et al. "Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania ‘major surface glycoprotein’ (gp63)." Veterinary Parasitology 60, no. 3-4 (1995): 199–212. http://dx.doi.org/10.1016/0304-4017(95)00788-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Velez, R., E. Domenech, J. Cairó, and M. Gállego. "The impact of canine leishmaniosis vaccination with Canileish® in Leishmania infantum infection seroprevalence studies." Acta Tropica 202 (February 2020): 105259. http://dx.doi.org/10.1016/j.actatropica.2019.105259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

IBORRA, S. "Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis." Vaccine 22, no. 29-30 (2004): 3865–76. http://dx.doi.org/10.1016/j.vaccine.2004.04.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wylie, C. E., M. Carbonell-Antoñanzas, E. Aiassa, et al. "A systematic review of the efficacy of prophylactic control measures for naturally-occurring canine leishmaniosis, part I: Vaccinations." Preventive Veterinary Medicine 117, no. 1 (2014): 7–18. http://dx.doi.org/10.1016/j.prevetmed.2014.06.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bretscher, P. A., N. Ismail, J. N. Menon, C. A. Power, J. Uzonna, and G. Wei. "Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections." Cellular and Molecular Life Sciences CMLS 58, no. 12 (2001): 1879–96. http://dx.doi.org/10.1007/pl00000824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Thapa, Rinez, Subhasish Mondal, Joakim Riikonen, et al. "Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis." PLOS Neglected Tropical Diseases 15, no. 6 (2021): e0009533. http://dx.doi.org/10.1371/journal.pntd.0009533.

Full text

Abstract:

Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmaniases, but it is highly hydrophobic resulting in poor bioavailability and low therapeutic efficacy. Herein, we loaded the drug into silicon nanoparticles produced from barley husk, which is an agricultural residue and widely available. The buparvaquone-loaded nanoparticles were several times more select

APA, Harvard, Vancouver, ISO, and other styles

11

Agallou, Maria, Maritsa Margaroni, Stathis D. Kotsakis, and Evdokia Karagouni. "A Canine-Directed Chimeric Multi-Epitope Vaccine Induced Protective Immune Responses in BALB/c Mice Infected with Leishmania infantum." Vaccines 8, no. 3 (2020): 350. http://dx.doi.org/10.3390/vaccines8030350.

Full text

Abstract:

Leishmaniases are complex vector-borne diseases caused by intracellular parasites of the genus Leishmania. The visceral form of the disease affects both humans and canids in tropical, subtropical, and Mediterranean regions. One health approach has suggested that controlling zoonotic visceral leishmaniasis (ZVL) could have an impact on the reduction of the human incidence of visceral leishmaniasis (VL). Despite the fact that a preventive vaccination could help with leishmaniasis elimination, effective vaccines that are able to elicit protective immune responses are currently lacking. In the pre

APA, Harvard, Vancouver, ISO, and other styles

12

Loiseau, Philippe M., Sébastien Pomel, and Simon L. Croft. "Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis." Molecules 25, no. 18 (2020): 4123. http://dx.doi.org/10.3390/molecules25184123.

Full text

Abstract:

The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with a

APA, Harvard, Vancouver, ISO, and other styles

13

Moreira, Marcela L., Christiane Costa-Pereira, Marina Luiza Rodrigues Alves, et al. "Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes." Veterinary Parasitology 220 (April 2016): 33–45. http://dx.doi.org/10.1016/j.vetpar.2016.02.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Melby, Peter C., Jue Yang, Weiguo Zhao, Luis E. Perez, and Jun Cheng. "Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis." Infection and Immunity 69, no. 8 (2001): 4719–25. http://dx.doi.org/10.1128/iai.69.8.4719-4725.2001.

Full text

Abstract:

ABSTRACT The acquisition of immunity following subclinical or resolved infection with the intracellular parasite Leishmania donovani suggests that vaccination could prevent visceral leishmaniasis (VL). The LACK (Leishmania homolog of receptors for activated C kinase) antigen is of interest as a vaccine candidate for the leishmaniases because of its immunopathogenic role in murine L. major infection. Immunization of mice with a truncated (24-kDa) version of the 36-kDa LACK antigen, delivered in either protein or DNA form, was found previously to protect against cutaneous L. major infection by r

APA, Harvard, Vancouver, ISO, and other styles

15

Kaye, Paul, Ahmed Musa, Joseph Olobo, et al. "OC 8489 CLINICAL DEVELOPMENT OF A THERAPEUTIC VACCINE FOR PREVENTION OF POST KALA AZAR DERMAL LEISHMANIASIS." BMJ Global Health 4, Suppl 3 (2019): A9.2—A9. http://dx.doi.org/10.1136/bmjgh-2019-edc.22.

Full text

Abstract:

BackgroundThe leishmaniases represent a complex of human diseases, with 350 million people at risk of infection worldwide. Although the potential benefits of vaccination have been well-recognised, no human vaccine is registered. Post-kala azar dermal leishmaniasis (PKDL) is a chronic skin disease often following treatment for visceral leishmaniasis (VL). In addition to affecting quality of life, evidence suggests that PKDL patients may also act as reservoirs for VL transmission. Hence, PKDL vaccines may have a significant impact on disease burden. We recently developed a third-generation adeno

APA, Harvard, Vancouver, ISO, and other styles

16

"Leishmaniosis: an approach about the immunoglobulins and cytokines involved in infection and vaccination." Acta Veterinaria Brasilica 7, no. 3 (2013). http://dx.doi.org/10.21708/avb.2013.7.3.3354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Acero P, Víctor, Perla Ángel B, Esther Fonseca B, Lluís Ferrer, and Xavier Roura. "Canine Leishmaniosis: tools for diagnosis in veterinary practice in Colombia." Revista MVZ Córdoba, September 25, 2015, 4822–42. http://dx.doi.org/10.21897/rmvz.52.

Full text

Abstract:

ABSTRACT The objective of this article is to perform a critical analysis and guide veterinarians in the management of canine Leishmaniosis. A systematic literature review was performed between 2005 and 2014 including scientific papers which take into account experiences and reports of: pathogenesis, diagnosis, clinical presentation, treatment, vaccination, prevention and control strategies. We discuss the different aspects of VL management and aspects that should be taken into account depending on the country, after a patient is suspected or confirmed as positive, including the possibility of

APA, Harvard, Vancouver, ISO, and other styles

18

Tonui, W. K., S. S. Mpoke, S. J. Turco, P. A. Mbati, and G. M. Mkoji. "Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB/c mice against Leishmania donovani." Onderstepoort J Vet Res 70, no. 4 (2003). http://dx.doi.org/10.4102/ojvr.v70i4.290.

Full text

Abstract:

The efficacy of Leishmania donovani-derived lipophosphoglycan (LPG) plus Mycobacterium bovis Bacille Calmette-Guérin (BCG) as a vaccine candidate against visceral leishmaniosis in susceptible BALB/c mouse and Syrian golden hamster (Mesocricetus auratus) models was investigated. Following a triple vaccination with a total dose of 150 µl BCG plus 60 µg or 30 µg of LPG for hamsters and BALB/c mice respectively, there were no noticeable side effects both locally and systemically; implying that the molecule was safe at this dosage level. Vaccinated animals demonstrated an activation of both the hum

APA, Harvard, Vancouver, ISO, and other styles

19

IBORRA, S. "Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis." Vaccine, May 2004. http://dx.doi.org/10.1016/s0264-410x(04)00357-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Guedes, Deborah Carbonera, Manuel Hospinal Santiani, Joyce Carvalho, et al. "In silico and in vitro Evaluation of Mimetic Peptides as Potential Antigen Candidates for Prophylaxis of Leishmaniosis." Frontiers in Chemistry 8 (January 15, 2021). http://dx.doi.org/10.3389/fchem.2020.601409.

Full text

Abstract:

Antigen formulation is the main feature for the success of leishmaniosis diagnosis and vaccination, since the disease is caused by different parasite species that display particularities which determine their pathogenicity and virulence. It is desirable that the antigens are recognized by different antibodies and are immunogenic for almost all Leishmania species. To overcome this problem, we selected six potentially immunogenic peptides derived from Leishmania histones and parasite membrane molecules obtained by phage display or spot synthesis and entrapped in liposome structures. We used thes

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!